Analyst firms · Barclays · OSCR

Barclays OSCR price target and rating history

Oscar Health Inc. (OSCR) · Health Care

Barclays rates Oscar Health Inc. (OSCR) Overweight with a $35 price target, as of its latest action on Jun 10, 2026. It has published 3 rating actions on OSCR since July 2025, including 2 upgrades and 0 downgrades. Across 7 firms with a OSCR price target in the last 12 months, the median target is $18. Barclays's $35 is 94% above that.

Current rating
Overweight
Price target
$35
Median target, all firms
$18
Actions on OSCR
3

Barclays price target on OSCR

$35$26$172026
Barclays price target on OSCR, each point a stated target, July 2025 to June 2026.

Every Barclays rating on OSCR

How other firms rate OSCR

Each firm's latest rating and stated target in the last 12 months.

FirmRatingPrice targetDate
BarclaysOverweight$35Jun 10, 2026
Wells FargoEqual Weight$20Jun 4, 2026
Wolfe ResearchPeer PerformMay 6, 2026
JefferiesHold$16Apr 20, 2026
Raymond JamesOutperform$18Feb 12, 2026
UBSNeutral$17Jan 9, 2026
StephensEqual-Weight$17Dec 11, 2025
Piper SandlerOverweight$25Nov 26, 2025

Questions about Barclays and OSCR

What is Barclays's price target for OSCR?
Barclays's latest stated price target for Oscar Health Inc. (OSCR) is $35, from its action on Jun 10, 2026.
What is Barclays's rating on OSCR?
Barclays rates OSCR Overweight, a bullish rating, as of Jun 10, 2026.
When did Barclays last change its view on OSCR?
On Jun 10, 2026, Barclays upgrades to Overweight from Equal Weight, price target $35.
How does Barclays's OSCR target compare with other analysts?
Across 7 firms with a OSCR price target in the last 12 months, the median target is $18. Barclays's $35 is 94% above that.

More OSCR rating histories

All Barclays ratingsOSCR news and filingsEvery analyst firm

From rating actions in the Quantisnow feed. A target holds until the firm states a new one; a reiteration with no target keeps the last one. Not investment advice.